Slow Subcutaneous Release of Glatiramer Acetate or CD40-Targeting Peptide KGYY6 Is More Advantageous in Treating Ongoing Experimental Autoimmune Encephalomyelitis.

Find People
Find Research
Overview
Tutorials
FAQs
Edit My PROFILE
Login to PROFILES

History

Elevated plasma comple

Jenkins, Thomas

Pentaerythritol Tetran

Nozykowski, Mari

Slow Subcutaneous Rele

See All (58) pages

Contact Us
If you have any questions or feedback please contact us.

Slow Subcutaneous Release of Glatiramer Acetate or CD40-Targeting Peptide KGYY6 Is More Advantageous in Treating Ongoing Experimental Autoimmune Encephalomyelitis.

Vaitaitis GM, Wagner DH. Slow Subcutaneous Release of Glatiramer Acetate or CD40-Targeting Peptide KGYY6 Is More Advantageous in Treating Ongoing Experimental Autoimmune Encephalomyelitis. Neurol Int. 2024 Nov 20; 16(6):1540-1551.

View in: PubMed

authors with profiles

David H Wagner Jr.

Contact Us
CCTSI
About CCTSI
CCTSI Affiliated Institutions
National CTSA Consortium